CA1325590C - Concentrated stabilized microbubble-type ultrasonic imaging agent - Google Patents
Concentrated stabilized microbubble-type ultrasonic imaging agentInfo
- Publication number
- CA1325590C CA1325590C CA000581985A CA581985A CA1325590C CA 1325590 C CA1325590 C CA 1325590C CA 000581985 A CA000581985 A CA 000581985A CA 581985 A CA581985 A CA 581985A CA 1325590 C CA1325590 C CA 1325590C
- Authority
- CA
- Canada
- Prior art keywords
- microspheres
- imaging agent
- concentration
- microns
- diameters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012216 imaging agent Substances 0.000 title claims abstract description 38
- 239000004005 microsphere Substances 0.000 claims abstract description 82
- 239000006185 dispersion Substances 0.000 claims abstract description 18
- 239000012736 aqueous medium Substances 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 9
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000560 biocompatible material Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000021267 infertility disease Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 38
- 238000000527 sonication Methods 0.000 description 30
- 238000005187 foaming Methods 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 11
- 108010088751 Albumins Proteins 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
Abstract
ABSTRACT
A microbubble-type ultrasonic imaging agent is provided comprising a parenterally-administerable aqueous medium contain-ing a dispersion of microspheres predominantly of diameters less than 10 microns, wherein the microspheres consist of gas micro-bubbles encapsulated with water-insolubilized biocompatible ma-terial. The imaging agent is characterized by having a concen-tration of greater than 100 x 106 microspheres per milliliter, and a stability such that this concentration is maintained for over 4 weeks at a temperature of 20 to 25°C.
A microbubble-type ultrasonic imaging agent is provided comprising a parenterally-administerable aqueous medium contain-ing a dispersion of microspheres predominantly of diameters less than 10 microns, wherein the microspheres consist of gas micro-bubbles encapsulated with water-insolubilized biocompatible ma-terial. The imaging agent is characterized by having a concen-tration of greater than 100 x 106 microspheres per milliliter, and a stability such that this concentration is maintained for over 4 weeks at a temperature of 20 to 25°C.
Description
(UIA-4) , CONC~NTRATED STABILIZED MICROBUBBLE-TYPE
ULTRASONIC IMAGING AGENT
This invention relates to ultrasonic imaging of the human body for diagnostic purposes; and, more particularly, to ultrasonic imaging agents.
- It has been known since 1968-70 that contrast echo-cardiography can be used to delineate intracardiac structures, assess valvular competence, demonstrate intracardiac shunts, and identify pericardial effusion. (Gramiak and Shah, 1968; and Fei-genbaum, et al., 1970.) Ultrasonic imaging of the heart poten-tially has important advantages of convenience, safety, and re-duced cost over present diagnostic procedures, such as angiogra-phy, which requires the use of radio-opaque dyes for X-ray imag-ing, or the use of radio-nuclide imaging agents for radio-imag-ing. However, progress in practical applications of ultrasonic imaging has been delayed by the lack of effective clinically-usable imaging agents.
Ultrasonic imaging utilizes an ultrasonic scanner to generate and receive sound waves. The scanner is placed on a body surface overlying the area to be imaged, and sound waves are directed toward that area. The scanner de~ects reflected sound waves and translates that data into images. When ultra-sonic energy is transmitted through a substance, the acoustic properties of the substance depend upon the velocity of the transmission and the density of the substance. Changes in the substance's acoustic properties (e.g., variations in acoustic impedence) are most prominent at the interfaces of different substances, such as a liquid-solid or liquid-gas interface.
Consequently, when ultrasonic energy is directed through media, changes in acoustic properties will result in more intense sound reflection signals for detection by the ultrasonic scanner.
Ultrasonic imaging agents can consist of small solid or gaseous particles which, when injected in the circulatory system, provide improved sound reflection and image clarity.
Microbubble-type imaging agents consist of minute bubbles of a gas (usually air) which are dispersed in a carrier liquid for ~ '.~ ' "' ' .
-~`` 132~90 parenteral injection. The "microbubbles" are carried by the circulatory system to the organ being imaged.
It has been proposed to form a dispersion of air micro-bubbles in a warm aqueous gelatin solution, and cooling the solu-tion to a solidification temperature to trap the microbubbles.
For administration, the ~elled d~spersion is to be warmed until it liquifies, and parenterally administered with the microbuh- ~ ---bles dispersed in the liauified gelatin. (Tickner, et al. U.S.
Patent 4,276,885; and Tickner, et al., National Technical Infor-mation Ser~ice Repor~ ~R-62917-lA, April, 1977).
Gelatin-trapped microbubbles on introduction into the bloodstream have a short life-time. They rapidly dissapate.
Another disadvantage is that the microbubbles are too large to pass through capillàry beds, and are therefore not suitable for heart imaging by peripheral intravenous administration.
~he discovery by Dr. Steven B. Feinstein of sonication- -produced microbubble imaging agents represented an important ad-vance in this art. Using viscous aqueous solutions, such as 70 sorbitol or dextrose, Dr. Feinstein produced a dispersion of microbubbles by high energy sonication of the solutions. The ``
resulting microbubbles had sizes less than 10 microns, and were ~;
capable of passing through capillary beds. The persistence of -the microbubbles, although of the order of a few minu~es, per-mitted the imaging agent to be pre~ared and administered intra-venously for heart imaging. (Feinstein, et al., 1984; and Feinstein U.S. Pate.nt 4,572,203.) Subsequen~ly, Dr. Feinstein sought to improve the per-sistence of the microbubbles. He found that hy sonication of a heat-sensitive protein, such as albumin, microbubbles of improved stability were obtained. (See Feinstein, published PCT Application W0 84/02838, corresponding to U.S. Patent No. 4,718,433 ~iled December 5, 1985).
Concentrations of microbubbles of 10 to 14 x 106 microbubbles per milliliter were obtained with bubble sizes from 2 to 9 microns (Keller, Feinstein, and Watson, 1987).
The microbubbles persisted for 24 to 48 hours.
., .
',:
" ~
1325~9~
However, the sonication-produced albumin microbubble imaging agent of Feinstein was not sufficiently stable for com-mercial manufacture. Stabilities of the order of weeks or months (rather than hours or days) are required to permit an imaging agent to be manufactured at a central location and dis-tributed to hospitals in the United States and other countries.
For commercially feasible manufacture, shipment and hospital storage prior to use, a stability time of at least four weeks is needed and pre~erably at least eight weeks or longer.
Further, for the most effec~ive imaging, it is desir-able to have the highest obtainable concentration of microbub-bles in the imaging agent. But the population of microbubbles of the desired small sizes tends to decrease with holding of the sonicated albumin solutions. The small bubble size attrition can occur either by collapse of the microbubbles, or by coales-ence to oversize microbubbles. Consequently a further important objective has been to find means for increasing concentrations of microbubbles in the imaging agent. An imaging agent of very high microbubble concentration is inherently better, and a safe-ty factor is provided. With a concentration of microbubbles higher than the minimum required for effective imaging, some -loss of the microbubbles of the desired size can be accepted.
The present invention provides an ultra-concentrated, room-temperature stable microbubble-type imaging agent. This improved imaging agent comprises a sterile aqueous medium con-taining a ~ispersion of microspheres predominately of diameters less than 10 microns, and is thereby suitable for parenteral intravenous administration. The microspheres consist of gas microbubbles encapsulated in a water-insolubilized biocompatible material, such as albumin. Representing a substantial advance in the art, the imaging agent of this invention has a homogene=
ously dispersed concentration of greater than 100 x 106 (e.g., 10 ) microspheres per milliliter. ~his high concentration can be maintained at ordinar~ room temperatures (20 to 25C) ~or ex-tended periods of time (4 to a weeks or longer). In optimized -l32~a embodiments, microspAere concentrations of the order of 300 to 500 x 106 microspheres per milliliter are achieved. Surprisin~-ly, these ultra-high concentrations can be maintained for over eight weeks. The imaging agents of this in~ention are therefore --adapted for manufacture and distribution on a commercial basis.
Following shipment, they may be maintained in inventory by hos-pitals for many ~eeks, being available for diagnostic use as re-quired.
The imagin~ agents of this invention are preferably produced from a heat-denaturable biocompatible protein by a step- ~-wise sonication procedure. As with the Feinstein method, an :
aqueous solution of protein is subjected to sonication to form gas microbubbles while concurrently heating the solution to in-solubilize small portions of the protein. However, the improved -sonication procedure, which results in the increased concentra-tion of highly stable microbubbles utilizes a novel sequential sonication. In the initial sonication phase, the sonicator horn is directly contacted with the solution (viz. by immersion just below the upper suface of the solution). This initial sonica-tion is carried out without appreciable foaming of the solution.
In the next phase of the sonication, foaming is promoted. The sonicator horn is withdrawn to a position in the ambient atmo-sphere above but proximate to the surface of the solution. In-tense foaming and aerosolating occurs. The population of micro-bubbles is thereby greatly increased and the microbubbles are encapsulated with denatured protein to obtain a dispersion of highly stable microspheres. Moreover, the stability of the microspheres permits them to be concentrated and/or fractionated.
By such manipulations, bubble concentration can be doubled or tripled and oversize bubbles eliminated.
For example, the concentration of the microspheres as initially produced can be from 50 to 150 x 106. By a float separation concentration procedure, the microsphere concentra-tion can be increased 200 to 600 x 106 microspheres per milli-liter. Also, by another float-type separation, most of the mic-robubbles of larger size than 10 microns can be removed, result- ~
:' ' ~: :
.. .. . .
.:
1325~
ing in an imaging agent composed predominately of microspheres of diameters substantially less than iO microns. For example, at least 80~i of the microspheres can have diameters in the range from 1 to 9 microns.
The accompanying drawings illustrate a preferred meth-od of preparing the ultrasound imaging agent of this invention.
FIGS. lA to lD illustrate the steps in the sequential sonication procedure.
FIG. 2 is a cross-sectional view taken on line 2-2 of FIG. lB, illustrating the relation of the sonicator horn to the inside of the syringe which contains the albumin solution being sonicated.
FIG. 3 illustrates a separator vessel in which incre-ments of the microsphere dispersions are pooled for float separa-tion concentration.
FIGS. 4, 4A, and 4B illustrate a method of fractiona-tion of microsphere dispersions to remove oversize microspheres.
FIG. 5 is a graph of experimental data showing the concentration of the microspheres in the imaging agent as pro-duced, and their storage stability.
The starting material for practicing this invention is an aqueous solution of a suitable biocompatible material. The encapsulating material should be heat-sensitive so that it can be partially insolubilized by heating during sonication. More specifically, coincident with the sonication, a small portion of the dissolved biocompatible material is heated or otherwise treated so that its solubility is reduced. This results in a small volume of solid phase material, which forms the encapsu-lating layers around the microspheres. Preferably a heat-sensitive protein is selected such as albumin, hemoglobin, col-lagen, etc. For administration to humans, human protein is pre-ferred. Human serum albumin (HSA) is especially suitable. HSA
is available commercially as a sterile 5% aqueous solution, which can be used directly as the starting material for preparing the ~ -microspheres. However, other concentrations of albumin or other heat-denaturable proteins can be used. HSA concentration can be varied, for example, within the range from 1 to 25% by weight.
Co~mercially-available sonicator equipment may be used - -in practicing this invention. Theoretically, sonicator vibra-tion frequencies can vary over a considerable range, such as from 5 to 30 kilo~erz (kHz), but most commercially-available sonicators operate at 2~ kHz or 10 kHz. The 20 kHz sonicators perform well for purpose of this in~ention. Such sonicator e-quipment can be obtained from Heat Systems-Ultrasonics, Inc., Farmingdale, New York, and other companies. Ultrasonics~Model W-380 or 5tmilar model can be used with a flat tip, high gain sonicator horn. The power applied to the sonicator horn can be varied over power settings scaled from 1 to 10 by the manufac-turer, as with Ultrasonics Model W-380. An intermediate power setting can be used (viz. from 4 to 8). The vibrational fre- -quency and the power applied must be sufficient to produce cavi- -tation in the liquid being sonicated.
The solution to be sonicated can be treated in small increments. For example, 8 ml. quantities of the solution can be individually sonicated. Initial sonication can be carried out with the flat-ended sonicator horn in contact with the solu-tion, preferably immersed in the upper portion of the solution.
Immersion is desirable in order to carry out the initial sonica-tion without appreciable foaming. With a power setting of 4 to 6, the initial sonication can be performed in less than a minute (viz. 15 to 45 seconds).
Immediately following the initial phase of the sonica-tion, the sonicator horn is withdrawn to a position above the solution but proximate to the upper surface of the solution. In the second phase, the sonication is deliberately carried out in such manner as to produce intense foaming of the solution, con-trary to con~entional sonlcations, where it is desirable to avoid foaming. Etor the purpose of the present invention, foam-ing and aerosolating are important for obtaining the imaging agent of enhanced concentration and stability.
To promote foaming, the power input to the sonicator horn may be increased in the second stage. For example, the power setting may be moved from an ~nitial setting of 4 to a setting of 6. The second phase of the sonication can be carried A
`, !. ~ t t 132~
out in less than a minute, (viz. from 15 to 45 seconds). The total time for the sonication for both the first and second phases can be o~ the order of one minute. ~or example, a 25 to 35 second sonic~ion can be used for each phase. The foaming produced in the second phase of the sonication is immediately detectable by the cloudy appearance of the solution, and ~y the foam produced.
By means of the sequential sonication, comprising the cavitation phase followed by a foaming phase, the concentration of the encapsulated microbubbles, referred to herein as "micro-spheres", can be greatly increased. Concentrations in excess of 25 x 106 microspheres per milliliter are easily obtainable, such ~ -as from 50 to 150 x 10 concentrations. Moreover, the resulting microspheres will be predominantly of diameters less than 10 microns. For example, 80% or more of the microspheres can have diameters in the range from 1 to 9 microns with a mean diameter of 4 to 6 microns.
When the son;cation is carried out in contact with air as the ambient atmosphere, the microspheres will have air cen-ters. Air is believed to be the most convenient ambient atmo-~phere, but, if desired, sonication could be carried out under other gas atmospheres (viz. nitrogen, oxygen, carbon dioxide, etc.).
Following initial production, the microsphere disper-sions can be further processed to increase the concentration and/or to remove oversize microspheres. Since the microspheres are buoyant they tend to rise to the surface of ~he dispersion.
By holding the dispersion without agitation for a number of hours, (viz. for 4 to 12 hours), most of the microspheres will rise to the surface and concen~rate in an upper layer above the clarified solution~ By this "float-separation" of the micro-spheres into an upper layer, portions of the clarified solution can be removed from below the microspheres, thereby obtaining a dispersion of greater microsphere concentration. For example, from 50 to 75% of the solution volume may be removed in this -concentration process.
:' 132559~
~ ither before or after the above-described concentra-tion, float-separation of oversized microspheres ca~ be obtained.
Large size microsphexes such as one having diameters greater than 10 microns have relatively greater buoyancy. They will therefore rise ~ore rapidly to the surface of the solution. By utilizing a short holding time, such as from 15 to 45 minutes, the largest siæe microspheres can be selectively collected in a small upper layer above a dispersion which will still contain substantially all of the microspheres of small size. By removing this microsphere dispersion from beneath the layer of oversize microspheres, a fractionation may be achieved in which the larger microspheres will remain in the vessel in which the frac-tionation is carried out.
The imaging agent produced by this combination of two-stage sonication and the float-separation concentration can have a homogeneously-dispersed concentration of greater than 300 x 106, such as from 300 to 900 x 106 (3 to 9 x 108) microspheres per milliliter. High concentrations can be maintained for long periods of holding at ambient room temperatures (20-25C). Con-centrations above 200 and typically above 300 x lQ6 microspheres per milliliter can be maintained for periods of at least four and usually eight weeks or longer.
In FIG. lA, there is shown a 10 ml syringe having an open top and a stopcock-type valve at its lower discharge end.
The syringe is filled to the 8 ml level with the 5% albumin (HSA) solution. The sonicator horn is inserted in the syringe to the 7 ml level, indicated as the Tl position in FIG. lB. In this position, the sonicator horn is immersed in the upper portion of the solution, the solution level being as indicated in FIG. lB.
Initial sonication is carried out essentially without foaming of the solution.
Immediately following initial sonication and without turning of~ the sonicator, the horn is withdrawn to the 10 ml level, indicated as the T2 position in FIG. lC. The power input to the sonicator horn c~n also ~e ~ncreased as it is withdrawn .' ~325~
g to the T2 position. Immediately following the withdrawal, foam-ing of the albumin solution commences and the solution becomes milky in appearance. The solution will foam upwardly around the sonicator horn during the second phase. The appearance of the foamed solution is illustrated in FIG. lD, the microbubbles be-ing indicated in greatly enlarged di~meter over their actual micron ranye sizes.
The solution being sonicated contains both dissolved and entrained air. The solution is in contact with the ambient atmostphere around the sonicator horn. (The clearance between the horn and the inside of the syringe can be seen in the cross-sectional view of FIG. 2.) The air contact facilitates the foaming and aerosolating of the solution in the second stage of the sonication.
The dispersions from a plurality of sonication batches can be pooled for concentration. For example, a plurality of the dispersion increments can be introduced into a separator vessel, which may be a large syringe or separator funnel equipped at its bottom with an outlet controlled by a drainage valve.
Such a separate vessel in the form of a large syringe is shown -in FIG. 3. By holding the pooled dispersions for several hours without agitation, such as overnight holding, the microspheres will rise to the top of the solution and form a layer of float-separated microspheres. Beneath the collected layer, the clari-fied albumin solution will be substantially free of microspheres.
It is therefore possible to drain off a major portion of the solution through the bottom outlet. For example, one-half to three-fourths of the solution can be removed. However, it is desirable to retain a sufficient solution volume to permit full redispersion of the concentrated microspheres.
In PIG. 4 illustrates the microsphere concentrate with the microspheres redispersed. The microspheres are sufficiently stable that they do not adhere permanently to each other in a concentrated layer, remaining as separate ~ntact microspheres.
They can readily be redispersed ~y mild agitation.
.,' ,:::
, ~32~59~
Aftex redispersion to an essentially homogeneous con-dition, fxactionation may be carried out to remove oversize mi-crospheres. ~y holding the redispersion ~or a short time, such as around 30 minutes, the largest diamete~ microspheres will pre~erentially rise to the top and colIect in a layer, as indi-cated in FIG. 4A. When that has occurred, the microsphere dis- -~
persion beneath the oversize microspheres can be removed through the drainage valve. When the collected oversize micro-spheres approach the valve, the valve is closed so that the oversize layer remains in the separator vessel, as indicated in FIG. 4B. The product obtained is a concentrated fractionated albumin m~crosphere product in which at least 80% of the micro-spheres have diameters in the range from 1 to 9 microns. The preferred product has at least 90% of the microspheres with di ameters of from 2 to 8 microns. -Further directional details of the presently preferred -procedures are set out below under the appropriate headings.
Sonication:
Fill a 10 ml syringe of oval cross-section fitted at its lower outlet end with a stopcock to the 8 ml mark with sterile 5% human serum albumin. Position a sonicator probe of smaller cross-section in the syringe so that the bottom of the probe is at the 7 ml mark. Sonicate at energy setting 6 for 30 seconds then (with the sonicator still on) move the probe tip to the 10 ml mark, while moving the energy setting to 8. Soni-cate for an additional 25 seconds. Turn off sonicator, remove probe and drain content~ of the syringe into a 60 ml syringe or separatory funnel with a stopcock controlled bottom outlet.
From 5 to 6 syringe volumes are pooled.
Concentration:
Allow the pooled increments to stand overnight (8-12 hours) ~tho~t agitation in the separator vessel. When substan-tially all the microspheres have ~ormed a layer on the top, drain two-thirds of the volume from the ~ottom.
1325~9~
Fractionatlon:
Resuspend the microspheres and fill a 60 ml syringe with them. Let sit 30 minutes, then drain all but about the last 3-4 ml into a collection vessel. The oversize microspheres are left. Count a sample and calculate the concentration, mean di-ameter, and percentage less than 10 ~. If less than 99.5% are less than 10~, re-fractionate. If required for redispersion, concentration may be ad~usted with 5% HS~.
.
RESULTS
Concentration measurements are set out below in Table A for three representative runs using the procedures described above. The initial concentration of the disperions after soni-cation was of the order of 130 to 1~0 x 106/ml. This was in-creased by the float-separation concentration to 340 to 450 x 106/ml.
For product control, the microspheres may be counted by a Coulter Counter, obtainable from Coulter Electronics, Inc., Highleah, Florida (viz. Coulter Counter Model TAII). Micro-sphere counts set out above were determined in this way.
The stability of a representative product was examined in a study lasting for 20 weeks. The initial concentration was approximately 4.31 x 108 (431 x 106) microspheres per milliliter.
Concentration measurements were made at about weekly intervals.
The results are summarized in Table B. The measurements, which were made by means of a Coulter Counter, are presented graphi-cally in FIG. 5. The samples were held at ambient room tempera-ture (20-25C). The concentration of about 400 X106 microspheres per milliliter was maintained for 20 weeks. This evidences a high degree o f room temperature stability.
The stability of the microspheres can be affected by unusually hot or cold temperatures. However, even at tempera-tures as low as 4C or as high as 37C, microsphere concentra-tions in excess o 200 x 106/ml can be maintained for periods of eight weeks or longer. Nevertheless, for commercial distribution or long-term holding very high or low temperatures should be avoided. Room temperature holding is preferred. Temperature i~
::
~ 32~5~
protection~of the microspheres during C?hipment can be used.
TABLE A
Concentration Measurements Microspheres/ml Microspheres/ml RunsAfter Sonication After Concentration A135 x 106 386 x 106 : :
~141 x 106 4~3 x 106 C 133 x 106 440 x 1o6 .: :
132~59~ -TABLE B
Microsphere WeekConcentration x 108 1 4.49 2 4.20 3.86 4.25 6 4.06 7 4.12 8 3.92 9 ' 3.94 3.97 11 3.48 12 3.48 13 4.09 14 3 70 ; ;
4.92 17 4.15 18 3.99 19 4.14 ~;
; .,' . '' ~ i~:';"
; .
: ",''. ' ,-',"',':
1325~90 -REFERENCES
Feigenbaum, et al. (1970), Circulation 41:615-621 Feinstein, U.S. Patent 4,572,203.
Feinstein PCT Application WO 84/02838.
Feinstein, et al. (1984), J Am. Coll. Cardiol. 3:14-20.
Gramiak and Shah (1968), Invest. Radiol. 3:356-358.
Keller, Feinstein and Watson (1987), Amer. Heart J., 114:570-575.
Tickner et al. U.S. Patent 4,276,885.
Tickner et al., National Technical Information Service Report HR 62917-lA, April, 1977, pages 34-40.
ULTRASONIC IMAGING AGENT
This invention relates to ultrasonic imaging of the human body for diagnostic purposes; and, more particularly, to ultrasonic imaging agents.
- It has been known since 1968-70 that contrast echo-cardiography can be used to delineate intracardiac structures, assess valvular competence, demonstrate intracardiac shunts, and identify pericardial effusion. (Gramiak and Shah, 1968; and Fei-genbaum, et al., 1970.) Ultrasonic imaging of the heart poten-tially has important advantages of convenience, safety, and re-duced cost over present diagnostic procedures, such as angiogra-phy, which requires the use of radio-opaque dyes for X-ray imag-ing, or the use of radio-nuclide imaging agents for radio-imag-ing. However, progress in practical applications of ultrasonic imaging has been delayed by the lack of effective clinically-usable imaging agents.
Ultrasonic imaging utilizes an ultrasonic scanner to generate and receive sound waves. The scanner is placed on a body surface overlying the area to be imaged, and sound waves are directed toward that area. The scanner de~ects reflected sound waves and translates that data into images. When ultra-sonic energy is transmitted through a substance, the acoustic properties of the substance depend upon the velocity of the transmission and the density of the substance. Changes in the substance's acoustic properties (e.g., variations in acoustic impedence) are most prominent at the interfaces of different substances, such as a liquid-solid or liquid-gas interface.
Consequently, when ultrasonic energy is directed through media, changes in acoustic properties will result in more intense sound reflection signals for detection by the ultrasonic scanner.
Ultrasonic imaging agents can consist of small solid or gaseous particles which, when injected in the circulatory system, provide improved sound reflection and image clarity.
Microbubble-type imaging agents consist of minute bubbles of a gas (usually air) which are dispersed in a carrier liquid for ~ '.~ ' "' ' .
-~`` 132~90 parenteral injection. The "microbubbles" are carried by the circulatory system to the organ being imaged.
It has been proposed to form a dispersion of air micro-bubbles in a warm aqueous gelatin solution, and cooling the solu-tion to a solidification temperature to trap the microbubbles.
For administration, the ~elled d~spersion is to be warmed until it liquifies, and parenterally administered with the microbuh- ~ ---bles dispersed in the liauified gelatin. (Tickner, et al. U.S.
Patent 4,276,885; and Tickner, et al., National Technical Infor-mation Ser~ice Repor~ ~R-62917-lA, April, 1977).
Gelatin-trapped microbubbles on introduction into the bloodstream have a short life-time. They rapidly dissapate.
Another disadvantage is that the microbubbles are too large to pass through capillàry beds, and are therefore not suitable for heart imaging by peripheral intravenous administration.
~he discovery by Dr. Steven B. Feinstein of sonication- -produced microbubble imaging agents represented an important ad-vance in this art. Using viscous aqueous solutions, such as 70 sorbitol or dextrose, Dr. Feinstein produced a dispersion of microbubbles by high energy sonication of the solutions. The ``
resulting microbubbles had sizes less than 10 microns, and were ~;
capable of passing through capillary beds. The persistence of -the microbubbles, although of the order of a few minu~es, per-mitted the imaging agent to be pre~ared and administered intra-venously for heart imaging. (Feinstein, et al., 1984; and Feinstein U.S. Pate.nt 4,572,203.) Subsequen~ly, Dr. Feinstein sought to improve the per-sistence of the microbubbles. He found that hy sonication of a heat-sensitive protein, such as albumin, microbubbles of improved stability were obtained. (See Feinstein, published PCT Application W0 84/02838, corresponding to U.S. Patent No. 4,718,433 ~iled December 5, 1985).
Concentrations of microbubbles of 10 to 14 x 106 microbubbles per milliliter were obtained with bubble sizes from 2 to 9 microns (Keller, Feinstein, and Watson, 1987).
The microbubbles persisted for 24 to 48 hours.
., .
',:
" ~
1325~9~
However, the sonication-produced albumin microbubble imaging agent of Feinstein was not sufficiently stable for com-mercial manufacture. Stabilities of the order of weeks or months (rather than hours or days) are required to permit an imaging agent to be manufactured at a central location and dis-tributed to hospitals in the United States and other countries.
For commercially feasible manufacture, shipment and hospital storage prior to use, a stability time of at least four weeks is needed and pre~erably at least eight weeks or longer.
Further, for the most effec~ive imaging, it is desir-able to have the highest obtainable concentration of microbub-bles in the imaging agent. But the population of microbubbles of the desired small sizes tends to decrease with holding of the sonicated albumin solutions. The small bubble size attrition can occur either by collapse of the microbubbles, or by coales-ence to oversize microbubbles. Consequently a further important objective has been to find means for increasing concentrations of microbubbles in the imaging agent. An imaging agent of very high microbubble concentration is inherently better, and a safe-ty factor is provided. With a concentration of microbubbles higher than the minimum required for effective imaging, some -loss of the microbubbles of the desired size can be accepted.
The present invention provides an ultra-concentrated, room-temperature stable microbubble-type imaging agent. This improved imaging agent comprises a sterile aqueous medium con-taining a ~ispersion of microspheres predominately of diameters less than 10 microns, and is thereby suitable for parenteral intravenous administration. The microspheres consist of gas microbubbles encapsulated in a water-insolubilized biocompatible material, such as albumin. Representing a substantial advance in the art, the imaging agent of this invention has a homogene=
ously dispersed concentration of greater than 100 x 106 (e.g., 10 ) microspheres per milliliter. ~his high concentration can be maintained at ordinar~ room temperatures (20 to 25C) ~or ex-tended periods of time (4 to a weeks or longer). In optimized -l32~a embodiments, microspAere concentrations of the order of 300 to 500 x 106 microspheres per milliliter are achieved. Surprisin~-ly, these ultra-high concentrations can be maintained for over eight weeks. The imaging agents of this in~ention are therefore --adapted for manufacture and distribution on a commercial basis.
Following shipment, they may be maintained in inventory by hos-pitals for many ~eeks, being available for diagnostic use as re-quired.
The imagin~ agents of this invention are preferably produced from a heat-denaturable biocompatible protein by a step- ~-wise sonication procedure. As with the Feinstein method, an :
aqueous solution of protein is subjected to sonication to form gas microbubbles while concurrently heating the solution to in-solubilize small portions of the protein. However, the improved -sonication procedure, which results in the increased concentra-tion of highly stable microbubbles utilizes a novel sequential sonication. In the initial sonication phase, the sonicator horn is directly contacted with the solution (viz. by immersion just below the upper suface of the solution). This initial sonica-tion is carried out without appreciable foaming of the solution.
In the next phase of the sonication, foaming is promoted. The sonicator horn is withdrawn to a position in the ambient atmo-sphere above but proximate to the surface of the solution. In-tense foaming and aerosolating occurs. The population of micro-bubbles is thereby greatly increased and the microbubbles are encapsulated with denatured protein to obtain a dispersion of highly stable microspheres. Moreover, the stability of the microspheres permits them to be concentrated and/or fractionated.
By such manipulations, bubble concentration can be doubled or tripled and oversize bubbles eliminated.
For example, the concentration of the microspheres as initially produced can be from 50 to 150 x 106. By a float separation concentration procedure, the microsphere concentra-tion can be increased 200 to 600 x 106 microspheres per milli-liter. Also, by another float-type separation, most of the mic-robubbles of larger size than 10 microns can be removed, result- ~
:' ' ~: :
.. .. . .
.:
1325~
ing in an imaging agent composed predominately of microspheres of diameters substantially less than iO microns. For example, at least 80~i of the microspheres can have diameters in the range from 1 to 9 microns.
The accompanying drawings illustrate a preferred meth-od of preparing the ultrasound imaging agent of this invention.
FIGS. lA to lD illustrate the steps in the sequential sonication procedure.
FIG. 2 is a cross-sectional view taken on line 2-2 of FIG. lB, illustrating the relation of the sonicator horn to the inside of the syringe which contains the albumin solution being sonicated.
FIG. 3 illustrates a separator vessel in which incre-ments of the microsphere dispersions are pooled for float separa-tion concentration.
FIGS. 4, 4A, and 4B illustrate a method of fractiona-tion of microsphere dispersions to remove oversize microspheres.
FIG. 5 is a graph of experimental data showing the concentration of the microspheres in the imaging agent as pro-duced, and their storage stability.
The starting material for practicing this invention is an aqueous solution of a suitable biocompatible material. The encapsulating material should be heat-sensitive so that it can be partially insolubilized by heating during sonication. More specifically, coincident with the sonication, a small portion of the dissolved biocompatible material is heated or otherwise treated so that its solubility is reduced. This results in a small volume of solid phase material, which forms the encapsu-lating layers around the microspheres. Preferably a heat-sensitive protein is selected such as albumin, hemoglobin, col-lagen, etc. For administration to humans, human protein is pre-ferred. Human serum albumin (HSA) is especially suitable. HSA
is available commercially as a sterile 5% aqueous solution, which can be used directly as the starting material for preparing the ~ -microspheres. However, other concentrations of albumin or other heat-denaturable proteins can be used. HSA concentration can be varied, for example, within the range from 1 to 25% by weight.
Co~mercially-available sonicator equipment may be used - -in practicing this invention. Theoretically, sonicator vibra-tion frequencies can vary over a considerable range, such as from 5 to 30 kilo~erz (kHz), but most commercially-available sonicators operate at 2~ kHz or 10 kHz. The 20 kHz sonicators perform well for purpose of this in~ention. Such sonicator e-quipment can be obtained from Heat Systems-Ultrasonics, Inc., Farmingdale, New York, and other companies. Ultrasonics~Model W-380 or 5tmilar model can be used with a flat tip, high gain sonicator horn. The power applied to the sonicator horn can be varied over power settings scaled from 1 to 10 by the manufac-turer, as with Ultrasonics Model W-380. An intermediate power setting can be used (viz. from 4 to 8). The vibrational fre- -quency and the power applied must be sufficient to produce cavi- -tation in the liquid being sonicated.
The solution to be sonicated can be treated in small increments. For example, 8 ml. quantities of the solution can be individually sonicated. Initial sonication can be carried out with the flat-ended sonicator horn in contact with the solu-tion, preferably immersed in the upper portion of the solution.
Immersion is desirable in order to carry out the initial sonica-tion without appreciable foaming. With a power setting of 4 to 6, the initial sonication can be performed in less than a minute (viz. 15 to 45 seconds).
Immediately following the initial phase of the sonica-tion, the sonicator horn is withdrawn to a position above the solution but proximate to the upper surface of the solution. In the second phase, the sonication is deliberately carried out in such manner as to produce intense foaming of the solution, con-trary to con~entional sonlcations, where it is desirable to avoid foaming. Etor the purpose of the present invention, foam-ing and aerosolating are important for obtaining the imaging agent of enhanced concentration and stability.
To promote foaming, the power input to the sonicator horn may be increased in the second stage. For example, the power setting may be moved from an ~nitial setting of 4 to a setting of 6. The second phase of the sonication can be carried A
`, !. ~ t t 132~
out in less than a minute, (viz. from 15 to 45 seconds). The total time for the sonication for both the first and second phases can be o~ the order of one minute. ~or example, a 25 to 35 second sonic~ion can be used for each phase. The foaming produced in the second phase of the sonication is immediately detectable by the cloudy appearance of the solution, and ~y the foam produced.
By means of the sequential sonication, comprising the cavitation phase followed by a foaming phase, the concentration of the encapsulated microbubbles, referred to herein as "micro-spheres", can be greatly increased. Concentrations in excess of 25 x 106 microspheres per milliliter are easily obtainable, such ~ -as from 50 to 150 x 10 concentrations. Moreover, the resulting microspheres will be predominantly of diameters less than 10 microns. For example, 80% or more of the microspheres can have diameters in the range from 1 to 9 microns with a mean diameter of 4 to 6 microns.
When the son;cation is carried out in contact with air as the ambient atmosphere, the microspheres will have air cen-ters. Air is believed to be the most convenient ambient atmo-~phere, but, if desired, sonication could be carried out under other gas atmospheres (viz. nitrogen, oxygen, carbon dioxide, etc.).
Following initial production, the microsphere disper-sions can be further processed to increase the concentration and/or to remove oversize microspheres. Since the microspheres are buoyant they tend to rise to the surface of ~he dispersion.
By holding the dispersion without agitation for a number of hours, (viz. for 4 to 12 hours), most of the microspheres will rise to the surface and concen~rate in an upper layer above the clarified solution~ By this "float-separation" of the micro-spheres into an upper layer, portions of the clarified solution can be removed from below the microspheres, thereby obtaining a dispersion of greater microsphere concentration. For example, from 50 to 75% of the solution volume may be removed in this -concentration process.
:' 132559~
~ ither before or after the above-described concentra-tion, float-separation of oversized microspheres ca~ be obtained.
Large size microsphexes such as one having diameters greater than 10 microns have relatively greater buoyancy. They will therefore rise ~ore rapidly to the surface of the solution. By utilizing a short holding time, such as from 15 to 45 minutes, the largest siæe microspheres can be selectively collected in a small upper layer above a dispersion which will still contain substantially all of the microspheres of small size. By removing this microsphere dispersion from beneath the layer of oversize microspheres, a fractionation may be achieved in which the larger microspheres will remain in the vessel in which the frac-tionation is carried out.
The imaging agent produced by this combination of two-stage sonication and the float-separation concentration can have a homogeneously-dispersed concentration of greater than 300 x 106, such as from 300 to 900 x 106 (3 to 9 x 108) microspheres per milliliter. High concentrations can be maintained for long periods of holding at ambient room temperatures (20-25C). Con-centrations above 200 and typically above 300 x lQ6 microspheres per milliliter can be maintained for periods of at least four and usually eight weeks or longer.
In FIG. lA, there is shown a 10 ml syringe having an open top and a stopcock-type valve at its lower discharge end.
The syringe is filled to the 8 ml level with the 5% albumin (HSA) solution. The sonicator horn is inserted in the syringe to the 7 ml level, indicated as the Tl position in FIG. lB. In this position, the sonicator horn is immersed in the upper portion of the solution, the solution level being as indicated in FIG. lB.
Initial sonication is carried out essentially without foaming of the solution.
Immediately following initial sonication and without turning of~ the sonicator, the horn is withdrawn to the 10 ml level, indicated as the T2 position in FIG. lC. The power input to the sonicator horn c~n also ~e ~ncreased as it is withdrawn .' ~325~
g to the T2 position. Immediately following the withdrawal, foam-ing of the albumin solution commences and the solution becomes milky in appearance. The solution will foam upwardly around the sonicator horn during the second phase. The appearance of the foamed solution is illustrated in FIG. lD, the microbubbles be-ing indicated in greatly enlarged di~meter over their actual micron ranye sizes.
The solution being sonicated contains both dissolved and entrained air. The solution is in contact with the ambient atmostphere around the sonicator horn. (The clearance between the horn and the inside of the syringe can be seen in the cross-sectional view of FIG. 2.) The air contact facilitates the foaming and aerosolating of the solution in the second stage of the sonication.
The dispersions from a plurality of sonication batches can be pooled for concentration. For example, a plurality of the dispersion increments can be introduced into a separator vessel, which may be a large syringe or separator funnel equipped at its bottom with an outlet controlled by a drainage valve.
Such a separate vessel in the form of a large syringe is shown -in FIG. 3. By holding the pooled dispersions for several hours without agitation, such as overnight holding, the microspheres will rise to the top of the solution and form a layer of float-separated microspheres. Beneath the collected layer, the clari-fied albumin solution will be substantially free of microspheres.
It is therefore possible to drain off a major portion of the solution through the bottom outlet. For example, one-half to three-fourths of the solution can be removed. However, it is desirable to retain a sufficient solution volume to permit full redispersion of the concentrated microspheres.
In PIG. 4 illustrates the microsphere concentrate with the microspheres redispersed. The microspheres are sufficiently stable that they do not adhere permanently to each other in a concentrated layer, remaining as separate ~ntact microspheres.
They can readily be redispersed ~y mild agitation.
.,' ,:::
, ~32~59~
Aftex redispersion to an essentially homogeneous con-dition, fxactionation may be carried out to remove oversize mi-crospheres. ~y holding the redispersion ~or a short time, such as around 30 minutes, the largest diamete~ microspheres will pre~erentially rise to the top and colIect in a layer, as indi-cated in FIG. 4A. When that has occurred, the microsphere dis- -~
persion beneath the oversize microspheres can be removed through the drainage valve. When the collected oversize micro-spheres approach the valve, the valve is closed so that the oversize layer remains in the separator vessel, as indicated in FIG. 4B. The product obtained is a concentrated fractionated albumin m~crosphere product in which at least 80% of the micro-spheres have diameters in the range from 1 to 9 microns. The preferred product has at least 90% of the microspheres with di ameters of from 2 to 8 microns. -Further directional details of the presently preferred -procedures are set out below under the appropriate headings.
Sonication:
Fill a 10 ml syringe of oval cross-section fitted at its lower outlet end with a stopcock to the 8 ml mark with sterile 5% human serum albumin. Position a sonicator probe of smaller cross-section in the syringe so that the bottom of the probe is at the 7 ml mark. Sonicate at energy setting 6 for 30 seconds then (with the sonicator still on) move the probe tip to the 10 ml mark, while moving the energy setting to 8. Soni-cate for an additional 25 seconds. Turn off sonicator, remove probe and drain content~ of the syringe into a 60 ml syringe or separatory funnel with a stopcock controlled bottom outlet.
From 5 to 6 syringe volumes are pooled.
Concentration:
Allow the pooled increments to stand overnight (8-12 hours) ~tho~t agitation in the separator vessel. When substan-tially all the microspheres have ~ormed a layer on the top, drain two-thirds of the volume from the ~ottom.
1325~9~
Fractionatlon:
Resuspend the microspheres and fill a 60 ml syringe with them. Let sit 30 minutes, then drain all but about the last 3-4 ml into a collection vessel. The oversize microspheres are left. Count a sample and calculate the concentration, mean di-ameter, and percentage less than 10 ~. If less than 99.5% are less than 10~, re-fractionate. If required for redispersion, concentration may be ad~usted with 5% HS~.
.
RESULTS
Concentration measurements are set out below in Table A for three representative runs using the procedures described above. The initial concentration of the disperions after soni-cation was of the order of 130 to 1~0 x 106/ml. This was in-creased by the float-separation concentration to 340 to 450 x 106/ml.
For product control, the microspheres may be counted by a Coulter Counter, obtainable from Coulter Electronics, Inc., Highleah, Florida (viz. Coulter Counter Model TAII). Micro-sphere counts set out above were determined in this way.
The stability of a representative product was examined in a study lasting for 20 weeks. The initial concentration was approximately 4.31 x 108 (431 x 106) microspheres per milliliter.
Concentration measurements were made at about weekly intervals.
The results are summarized in Table B. The measurements, which were made by means of a Coulter Counter, are presented graphi-cally in FIG. 5. The samples were held at ambient room tempera-ture (20-25C). The concentration of about 400 X106 microspheres per milliliter was maintained for 20 weeks. This evidences a high degree o f room temperature stability.
The stability of the microspheres can be affected by unusually hot or cold temperatures. However, even at tempera-tures as low as 4C or as high as 37C, microsphere concentra-tions in excess o 200 x 106/ml can be maintained for periods of eight weeks or longer. Nevertheless, for commercial distribution or long-term holding very high or low temperatures should be avoided. Room temperature holding is preferred. Temperature i~
::
~ 32~5~
protection~of the microspheres during C?hipment can be used.
TABLE A
Concentration Measurements Microspheres/ml Microspheres/ml RunsAfter Sonication After Concentration A135 x 106 386 x 106 : :
~141 x 106 4~3 x 106 C 133 x 106 440 x 1o6 .: :
132~59~ -TABLE B
Microsphere WeekConcentration x 108 1 4.49 2 4.20 3.86 4.25 6 4.06 7 4.12 8 3.92 9 ' 3.94 3.97 11 3.48 12 3.48 13 4.09 14 3 70 ; ;
4.92 17 4.15 18 3.99 19 4.14 ~;
; .,' . '' ~ i~:';"
; .
: ",''. ' ,-',"',':
1325~90 -REFERENCES
Feigenbaum, et al. (1970), Circulation 41:615-621 Feinstein, U.S. Patent 4,572,203.
Feinstein PCT Application WO 84/02838.
Feinstein, et al. (1984), J Am. Coll. Cardiol. 3:14-20.
Gramiak and Shah (1968), Invest. Radiol. 3:356-358.
Keller, Feinstein and Watson (1987), Amer. Heart J., 114:570-575.
Tickner et al. U.S. Patent 4,276,885.
Tickner et al., National Technical Information Service Report HR 62917-lA, April, 1977, pages 34-40.
Claims (10)
1. A concentrated room-temperature stable ultrasonic imaging agent comprising a parenterally administerable aqueous medium containing a dispersion of microspheres predominantly of diameters less than 10 microns, which microspheres consist of gas microbubbles encapsulated with water-insolubilized biocom-patible material, said imaging agent having a homogeneously dis-persed concentration of greater than 100 x 106 microspheres per milliliter and which maintains such concentration for over 4 weeks at a temperature of 20 to 25°C.
2. The imaging agent of claim 1 in which at least 80%
of said microspheres have diameters in the range from 1 to 9 microns.
of said microspheres have diameters in the range from 1 to 9 microns.
3. The imaging agent of claim 1 or claim 2 which has a homogeneously dispersed concentration of said microspheres greater than 200 x 106 microspheres per milliliter and which maintains such concentration for over 4 weeks at a temperature of 20 to 25°C.
4. The imaging agent of claim 1 or claim 2 in which said microbubbles are encapsulated with human serum albumin.
5. A concentrated room-temperature stable ultrasonic imaging agent comprising a parenterally administrable aqueous soluttion of a heat-denaturable biocompatible protein containing a dispersion of microspheres at least 80% of which have diameters in the range of 1 to 9 microns, said microspheres consisting of an air microbubble encapsulated in a heat-insolubilized layer of said protein, said imaging agent having a homogeneously-dispersed concentrattion greater than 200 x 106 microspheres per milliliter and which maintains such concentration for over 4 weeks at a tem-perature of 20 to 25°C.
6. The imaging agent of claim 5 which has a homogen-eously dispersed concentration of from 300 to 600 x 106 micro-spheres per milliliter, and which maintains such concentration for at least 8 weeks at a temperature of 20 to 25°C.
7. The imaging agent of claim 5 or claim 6 in which said protein is human serum albumin.
8. The imaging agent of claim 5 or claim 6 in which 90% or more of said microspheres have diameters in the range from 2 to 8 microns.
9. A concentrated room-temperature stable ultrasonic imaging agent for intravenous administration, comprising a ster-ile aqueous solution of human serum albumin containing a disper-sion of microspheres at least 80% of which have diameters in the range of 1 to 9 microns, said microspheres consisting of a bubble of air encapsulated in a water-insolubilized layer of said al-bumin, said imaging agent having a homogeneously-dispersed con-centration of from 300 to 600 x 106 microspheres per milliliter and which maintains such concentration for at least 8 weeks at a temperature of 20 to 25°C.
10. The imaging agent of claim 9 in which at least 90%
of said microspheres have diameters in the range from 2 to 8 microns.
of said microspheres have diameters in the range from 2 to 8 microns.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/139,576 US4844882A (en) | 1987-12-29 | 1987-12-29 | Concentrated stabilized microbubble-type ultrasonic imaging agent |
US139,576 | 1987-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1325590C true CA1325590C (en) | 1993-12-28 |
Family
ID=22487335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000581985A Expired - Lifetime CA1325590C (en) | 1987-12-29 | 1988-11-02 | Concentrated stabilized microbubble-type ultrasonic imaging agent |
Country Status (6)
Country | Link |
---|---|
US (1) | US4844882A (en) |
JP (1) | JPH0662445B2 (en) |
KR (1) | KR960005709B1 (en) |
CN (1) | CN1028963C (en) |
CA (1) | CA1325590C (en) |
IL (1) | IL88039A (en) |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE58908194D1 (en) | 1988-02-05 | 1994-09-22 | Schering Ag | ULTRASONIC CONTRAST AGENTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS DIAGNOSTICS AND THERAPEUTICS. |
US5730954A (en) * | 1988-08-23 | 1998-03-24 | Schering Aktiengesellschaft | Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6001335A (en) * | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US20020150539A1 (en) | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5230882A (en) * | 1989-12-22 | 1993-07-27 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US6146657A (en) * | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
USRE39146E1 (en) * | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
IN172208B (en) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
US6613306B1 (en) * | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5948387A (en) * | 1990-06-01 | 1999-09-07 | Imarx Pharmaceutical Corp. | Contrast media for ultrasonic imaging |
US5420176A (en) * | 1990-06-01 | 1995-05-30 | Imarx Pharmaceutical Corp. | Contrast media for ultrasonic imaging |
DE69215722T3 (en) * | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5147631A (en) * | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
DE69230885T3 (en) * | 1991-09-17 | 2008-01-24 | Ge Healthcare As | GASOUS ULTRASONIC CONTRASTING AGENTS |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
MX9205298A (en) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA |
US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
US5233995A (en) * | 1991-11-21 | 1993-08-10 | Sterling Winthrop Inc. | Encapsulated particles useful as contrast agents in ultrasound and x-ray imaging compositions and methods |
US5196183A (en) * | 1991-12-04 | 1993-03-23 | Sterling Winthrop Inc. | Contrast agents for ultrasound imaging |
KR0127331B1 (en) * | 1991-12-19 | 1997-12-29 | 구자홍 | Control method and voice recording apparatus for message information and alarm system of watching distance of television system |
US5255683A (en) * | 1991-12-30 | 1993-10-26 | Sound Science Limited Partnership | Methods of and systems for examining tissue perfusion using ultrasonic contrast agents |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
JPH05262673A (en) * | 1992-03-19 | 1993-10-12 | Nippon Paint Co Ltd | Contrast medium for ultrasonic diagnosis |
WO1994007417A1 (en) * | 1992-10-06 | 1994-04-14 | Molecular Biosystems, Inc. | Method of ultrasonic imaging of body cavities |
GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
WO1994009703A1 (en) * | 1992-11-02 | 1994-05-11 | Drexel University | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same |
CZ191695A3 (en) * | 1993-01-25 | 1996-05-15 | Sonus Pharma Inc | Biologically compatible contrast agent, process of its preparation and representation method by ultrasound |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Phase shift colloids as ultrasound contrast agents |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
BR9405798A (en) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Methods for in vivo release of biological material and useful compositions thereof |
US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
US5695740A (en) * | 1993-05-12 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US5855865A (en) * | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
EP0711179B2 (en) | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
US5385147A (en) * | 1993-09-22 | 1995-01-31 | Molecular Biosystems, Inc. | Method of ultrasonic imaging of the gastrointestinal tract and upper abdominal organs using an orally administered negative contrast medium |
US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
HU225495B1 (en) | 1993-12-15 | 2007-01-29 | Bracco Research Sa | Gas mixtures useful as ultrasound contrast media |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US5876697A (en) * | 1994-08-04 | 1999-03-02 | Gakko Houjin Toin Gakuen | Method for the production of microbubble-type ultrasonic contrast agent using fatty acid surfactants |
WO1998053855A1 (en) * | 1997-05-30 | 1998-12-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for monitoring and quantifying the movement of fluid |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US5897851A (en) * | 1995-06-07 | 1999-04-27 | Sonus Pharmaceuticals, Inc. | Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging |
US5820850A (en) * | 1995-06-07 | 1998-10-13 | Molecular Biosystems, Inc. | Gas-filled amino acid block co-polymer microspheres useful as ultrasound contrast agents |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US5955143A (en) * | 1995-12-21 | 1999-09-21 | Drexel University | Hollow polymer microcapsules and method of producing the same |
AU721209B2 (en) * | 1996-03-05 | 2000-06-29 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
AU736301B2 (en) | 1996-05-01 | 2001-07-26 | Imarx Therapeutics, Inc. | Methods for delivering compounds into a cell |
US5976501A (en) * | 1996-06-07 | 1999-11-02 | Molecular Biosystems, Inc. | Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion |
CN1042700C (en) * | 1996-06-25 | 1999-03-31 | 谢峰 | Dextran albumin acoustical contrast medium containing perfluocarbon and its producing process |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
ATE366588T1 (en) * | 1996-09-11 | 2007-08-15 | Imarx Pharmaceutical Corp | METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
GB9708246D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Improvements in or relating to ultrasound imaging |
US6582392B1 (en) * | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
GB9813568D0 (en) | 1998-06-23 | 1998-08-19 | Nycomed Imaging As | Improvements in or relating to cardiac imaging |
US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
EP1289565B1 (en) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Compounds for targeting endothelial cells |
DE10036290A1 (en) * | 2000-07-26 | 2002-02-07 | Bosch Gmbh Robert | Device for determining at least one parameter of a flowing medium |
US6712805B2 (en) * | 2001-01-29 | 2004-03-30 | Ultra Sonic Tech Llc | Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound |
US6962071B2 (en) * | 2001-04-06 | 2005-11-08 | Bracco Research S.A. | Method for improved measurement of local physical parameters in a fluid-filled cavity |
DE10137515A1 (en) * | 2001-07-26 | 2003-02-13 | Diagnostikforschung Inst | Production of pharmaceutical preparations in charged particle dispersion form, e.g. contrast agent dispersion, including separation of particles using ion exchangers or by electrophoresis |
US20030031626A1 (en) * | 2001-07-26 | 2003-02-13 | Thomas Rheinlander | Process for the production of pharmaceutical preparations |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
ATE520362T1 (en) | 2001-12-03 | 2011-09-15 | Ekos Corp | CATHETER WITH MULTIPLE ULTRASONIC EMITTING PARTS |
CA2513044A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
CA2477836A1 (en) | 2002-03-01 | 2003-09-12 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
ATE343376T1 (en) * | 2002-03-20 | 2006-11-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
US6921371B2 (en) | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
CA2517939C (en) | 2003-03-03 | 2015-11-24 | Dyax Corp. | Peptides that specifically bind hgf receptor (cmet) and uses thereof |
US7341569B2 (en) | 2004-01-30 | 2008-03-11 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
CA2586130A1 (en) * | 2004-11-22 | 2006-05-26 | Oxygenix Co., Ltd. | Reagent containing oxygen isotope-labeled hemoglobin for examining vital tissue and method of producing the same |
CA2604380A1 (en) * | 2005-04-12 | 2006-10-19 | Ekos Corporation | Ultrasound catheter with cavitation promoting surface |
US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9358033B2 (en) | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US10548659B2 (en) | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
CA2621535A1 (en) * | 2005-09-07 | 2007-03-15 | The Foundry, Inc. | Apparatus and method for disrupting subcutaneous structures |
US7967763B2 (en) * | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
US20080195036A1 (en) * | 2005-12-02 | 2008-08-14 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US9248317B2 (en) * | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US20080200863A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US20080200864A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US7885793B2 (en) | 2007-05-22 | 2011-02-08 | International Business Machines Corporation | Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution |
US20080014627A1 (en) * | 2005-12-02 | 2008-01-17 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US20080197517A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
EP2015846A2 (en) | 2006-04-24 | 2009-01-21 | Ekos Corporation | Ultrasound therapy system |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
EP2494932B1 (en) | 2007-06-22 | 2020-05-20 | Ekos Corporation | Apparatus for treatment of intracranial hemorrhages |
US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
WO2011035140A1 (en) | 2009-09-18 | 2011-03-24 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of contrast moieties to the lungs |
US20120195833A1 (en) * | 2011-02-01 | 2012-08-02 | Chung Yuan Christian University | Medical Contrast Agent Made of Microbubbles Containing Fluorescent Gold Nanoclusters |
WO2012132140A1 (en) * | 2011-03-31 | 2012-10-04 | パナソニック株式会社 | Ultrasound contrast agent |
US10357450B2 (en) | 2012-04-06 | 2019-07-23 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
WO2014001297A2 (en) * | 2012-06-26 | 2014-01-03 | Ge Healthcare As | Preparation of composition comprising gas microbubbles |
WO2014144364A1 (en) | 2013-03-15 | 2014-09-18 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
US20160067276A1 (en) * | 2013-03-15 | 2016-03-10 | Children's Medical Center Corporation | Hollow particles encapsulating a biological gas and methods of use |
CN107708581B (en) | 2015-06-10 | 2021-11-19 | Ekos公司 | Ultrasonic wave guide tube |
WO2018160752A1 (en) | 2017-02-28 | 2018-09-07 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
US20220249667A1 (en) * | 2019-05-29 | 2022-08-11 | Drexel University | Microbubbles |
US11191888B1 (en) | 2020-05-18 | 2021-12-07 | Agitated Solutions Inc. | Syringe-based microbubble generator |
WO2022164927A1 (en) * | 2021-01-26 | 2022-08-04 | Agitated Solutions Inc. | Syringe-based microbubble generator with an aerator |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
-
1987
- 1987-12-29 US US07/139,576 patent/US4844882A/en not_active Expired - Lifetime
-
1988
- 1988-10-13 IL IL88039A patent/IL88039A/en active Protection Beyond IP Right Term
- 1988-11-02 CA CA000581985A patent/CA1325590C/en not_active Expired - Lifetime
- 1988-12-23 JP JP63323826A patent/JPH0662445B2/en not_active Expired - Fee Related
- 1988-12-28 KR KR1019880017665A patent/KR960005709B1/en not_active IP Right Cessation
- 1988-12-28 CN CN88105824A patent/CN1028963C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US4844882A (en) | 1989-07-04 |
JPH0662445B2 (en) | 1994-08-17 |
JPH01203337A (en) | 1989-08-16 |
CN1035774A (en) | 1989-09-27 |
IL88039A (en) | 1992-07-15 |
KR960005709B1 (en) | 1996-05-01 |
KR890009418A (en) | 1989-08-01 |
CN1028963C (en) | 1995-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1325590C (en) | Concentrated stabilized microbubble-type ultrasonic imaging agent | |
EP0324938B1 (en) | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production | |
US4957656A (en) | Continuous sonication method for preparing protein encapsulated microbubbles | |
JP2769077B2 (en) | Diagnostic imaging agent and method for preparing the same | |
US5855865A (en) | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas | |
JP3809368B2 (en) | Ultrasound imaging agent containing encapsulated microspheres | |
AU630030B2 (en) | Stable microbubbles suspensions injectable into living organisms | |
EP0835664A2 (en) | Improvements in or relating to contrast agents | |
US11123302B2 (en) | Formulation of acoustically activatable particles having low vaporization energy and methods for using same | |
CZ291540B6 (en) | Frozen suspension of gas bubbles immobilized within a frozen aqueous carrier medium, process of its preparation and use | |
CA2373869A1 (en) | Multi-stage method for producing gas-filled microcapsules | |
AU722742B2 (en) | Methods for making encapsulated microspheres from heat denatured protein using mechanical cavitation | |
AU7318498A (en) | Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |